Higher dose of Gilead-Galapagos drug meets ulcerative colitis study goals

Gilead Sciences Inc (GILD.O) and partner Galapagos NV (GLPG.AS) said on Wednesday only a higher dose of their experimental drug filgotinib showed greater effectiveness than placebo in a pivotal study testing it in ulcerative colitis patients. Filgotinib is also in advanced stages of testing against multiple types of inflammatory conditions including rheumatoid arthritis, a market […]

Continue Reading